alexa Alzheimer Disease And Neuroplasticity: New Approaches And New Targets
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

2nd International Conference on Alzheimers Disease and Dementia
September 23-25, 2014 Valencia Convention Centre, Spain

Tayfun Uzbay
ScientificTracks Abstracts: J Alzheimers Dis Parkinsonism
DOI: 10.4172/2161-0460.S1.006
Abstract
Alzheimer disease (AD) is the major cause of dementia in the aged individuals. It is a neurodegenerative disorder characterized by apoptosis and loss of neurons resulting in synaptic dysfunction in central pathways involved in learning and memory. Neuroplasticity can simply be defined as changes in the brain neurons, and structural and functional changes in synapses formed by these neurons. If the changes are not confined to a single neuron but reach the level of a synapse the adaptive response formed may also be called ?synaptic plasticity?. Brain is adapted to all exogenous and endogenous stimulations (i.e. environmental or emotional stresses) by neuroplasticity. The most essential statement on AD pathology is that it assault the processes associated with neuroplasticity in central nervous system (CNS). Directly focusing on the causes of damages of synaptic elements and development of new therapeutic approaches devoted to reverse impaired neuroplasticity induced by the disorder may be a more effective strategy and provide more consistent solutions in the treatment of AD. The main objective of this presentation is to update our knowledge on AD in the light of the present literature and discuss the new approaches and targets such as neuroplasticity hypothesis of AD and new candidate drugs.
Biography
Tayfun Uzbay is professor of Medical Pharmacology, head of the Departments of Neuroscience and director of the Neuropsychopharmacology Application and Research Center (NPARC) at Uskudar University in Istanbul. He worked in University of North Texas, Department of Pharmacology and Neuroscience in USA and University of Cagliari, Department of Toxicology in Italy as a visiting scientist. He is a founder of Psychopharmacology Research Unit in Turkey. His research studies have been focused on Behavioral Neurocience. He has patent of some new molecules in treatment of schizophrenia. He published more than a hundred international full papers and these papers have been cited more than 1600.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords